Specialty Overview

Best Hospitals for Immunotherapy for Cancer in Delhi NCR, India

35 cancer care hospitals in our India network are listed in Delhi NCR, accredited by JCI, NABH, NABL, ISO, with 17,362 beds combined.

35
Hospitals Listed
1
City
4.5
Avg. Rating
4
Accreditation Types
The Short Answer

This page lists the cancer care hospitals in our directory offering Immunotherapy for Cancer in Delhi NCR, India, including Apollo Hospitals, Medanta - The Medicity, Artemis Hospital, Fortis Memorial Research Institute and others. Each listing links through to the hospital's full profile page.

Ask us about immunotherapy for cancer in Delhi NCR, India

Share a few details and our care coordination team will get back to you with next steps.

Compare 35 accredited hospitals for Cancer Care in Delhi NCR, India

Starting from$1,000

🇮🇳 Apollo Hospitals

New Delhi, India 4.9 (1240 reviews) 1,000 beds
Why consider this hospital?
4.9/5 rating from 1240 reviewsAccredited by JCI, NABH1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Apollo Hospitals's care team in New Delhi, India, from initial consultation through recovery. Apollo Hospitals, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.9/5
Rating
1983
Established
1,000
Beds
New Delhi, India
Location
Medanta - The Medicity
Starting from$1,000

🇮🇳 Medanta - The Medicity

Gurgaon, India 4.9 (2150 reviews) 1,600 beds
Why consider this hospital?
4.9/5 rating from 2150 reviewsAccredited by JCI, NABH1,600 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Medanta - The Medicity's care team in Gurgaon, India, from initial consultation through recovery. Medanta - The Medicity, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.9/5
Rating
2009
Established
1,600
Beds
Gurgaon, India
Location
Artemis Hospital
Starting from$1,000

🇮🇳 Artemis Hospital

Gurgaon, India 4.9 (64 reviews) 750 beds
Why consider this hospital?
4.9/5 rating from 64 reviewsAccredited by JCI, NABH750 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Artemis Hospital's care team in Gurgaon, India, from initial consultation through recovery. Artemis Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.9/5
Rating
2007
Established
750
Beds
Gurgaon, India
Location
Fortis Memorial Research Institute
Starting from$1,000

🇮🇳 Fortis Memorial Research Institute

Gurgaon, India 4.8 (1100 reviews) 1,000 beds
Why consider this hospital?
4.8/5 rating from 1100 reviewsAccredited by JCI, NABH1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Fortis Memorial Research Institute's care team in Gurgaon, India, from initial consultation through recovery. Fortis Memorial Research Institute, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.8/5
Rating
1996
Established
1,000
Beds
Gurgaon, India
Location
Max Super Specialty Hospital
Starting from$1,000

🇮🇳 Max Super Specialty Hospital

New Delhi, India 4.8 (1300 reviews) 500 beds
Why consider this hospital?
4.8/5 rating from 1300 reviewsAccredited by JCI, NABH500 beds
Specialties & Accreditation
CardiacLiver Transplant
Accredited by JCI, NABH

Patients considering immunotherapy for cancer can be cared for by Max Super Specialty Hospital's care team in New Delhi, India, from initial consultation through recovery. Max Super Specialty Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.8/5
Rating
2000
Established
500
Beds
New Delhi, India
Location
All India Institute of Medical Sciences (AIIMS)
Starting from$1,000

🇮🇳 All India Institute of Medical Sciences (AIIMS)

New Delhi, India 4.7 (3500 reviews) 2,400 beds
Why consider this hospital?
4.7/5 rating from 3500 reviewsAccredited by NABH2,400 beds
Specialties & Accreditation
Multi-specialtyResearch
Accredited by NABH

Patients considering immunotherapy for cancer can be cared for by All India Institute of Medical Sciences (AIIMS)'s care team in New Delhi, India, from initial consultation through recovery. All India Institute of Medical Sciences (AIIMS), accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.7/5
Rating
1956
Established
2,400
Beds
New Delhi, India
Location
CK Birla Hospital
Starting from$1,000

🇮🇳 CK Birla Hospital

Gurugram, Haryana, India 4.7 (162 reviews) 90 beds
Why consider this hospital?
4.7/5 rating from 162 reviewsAccredited by NABH90 beds
Specialties & Accreditation
Obstetrics & GynecologyOrthopedicsCardiac SciencesOncologyPediatrics
Accredited by NABH

Patients considering immunotherapy for cancer can be cared for by CK Birla Hospital's care team in Gurugram, Haryana, India, from initial consultation through recovery. CK Birla Hospital, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.7/5
Rating
2017
Established
90
Beds
Gurugram, Haryana, India
Location
Centre for Sight
Starting from$1,000

🇮🇳 Centre for Sight

Safdarjung Enclave, New Delhi, India 4.7 (181 reviews) 30 beds
Why consider this hospital?
4.7/5 rating from 181 reviewsAccredited by NABH30 beds
Specialties & Accreditation
LASIK SurgeryRetina SurgeryCataract SurgeryGlaucomaCornea Transplant
Accredited by NABH

Patients considering immunotherapy for cancer can be cared for by Centre for Sight's care team in Safdarjung Enclave, New Delhi, India, from initial consultation through recovery. Centre for Sight, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.7/5
Rating
1996
Established
30
Beds
Safdarjung Enclave, New Delhi, India
Location
Max Super Specialty Hospital, Gurgaon
Starting from$1,000

🇮🇳 Max Super Specialty Hospital, Gurgaon

Gurgaon, India 4.6 (95 reviews) 104 beds
Why consider this hospital?
4.6/5 rating from 95 reviewsAccredited by NABH, JCI104 beds
Specialties & Accreditation
Cardiac SciencesOncologyOrthopedicsNeurosciencesTransplant
Accredited by NABH, JCI

Patients considering immunotherapy for cancer can be cared for by Max Super Specialty Hospital, Gurgaon's care team in Gurgaon, India, from initial consultation through recovery. Max Super Specialty Hospital, Gurgaon, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.6/5
Rating
2007
Established
104
Beds
Gurgaon, India
Location
Max Super Speciality Hospital, Patparganj
Starting from$1,000

🇮🇳 Max Super Speciality Hospital, Patparganj

Patparganj, New Delhi, India 4.6 (97 reviews) 400 beds
Why consider this hospital?
4.6/5 rating from 97 reviewsAccredited by NABH, JCI400 beds
Specialties & Accreditation
Cardiac SciencesOncologyOrthopedicsNeurosciencesTransplant
Accredited by NABH, JCI

Patients considering immunotherapy for cancer can be cared for by Max Super Speciality Hospital, Patparganj's care team in Patparganj, New Delhi, India, from initial consultation through recovery. Max Super Speciality Hospital, Patparganj, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing immunotherapy for cancer.

4.6/5
Rating
2005
Established
400
Beds
Patparganj, New Delhi, India
Location
Our Methodology

How we selected these hospitals

A hospital appears on this page when Cancer Care is among its listed specialties and it is located in Delhi NCR, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Immunotherapy for Cancer in Delhi NCR, India?

Choosing the right hospital for immunotherapy for cancer is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include cancer care rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Immunotherapy for Cancer

Cancer immunotherapy harnesses the body's own immune system to identify, attack, and eliminate malignant cells — representing one of the most significant paradigm shifts in oncology over the past two decades.

3–7 days per treatment cycle (outpatient infusions are common; inpatient admission required for CAR-T cell therapy and high-grade immune-related adverse events)
Hospital Stay
2–6 weeks minimum before international travel is medically cleared; CAR-T recipients typically require 4–8 weeks of local monitoring post-infusion
Total Stay in Country (Fit-to-Fly)
Objective response rates range from 15–45% for solid tumors with PD-1/PD-L1 checkpoint inhibitors; 70–85% complete remission rates reported for relapsed/refractory B-cell lymphoma with CAR-T (axicabtagene ciloleucel / tisagenlecleucel); outcomes are highly cancer-type and biomarker dependent
Success Rate

Clinical Overview

  • Cancer immunotherapy is a class of treatments that modulates or augments the immune system's capacity to recognize tumor-associated antigens (TAAs) and mount a sustained cytotoxic response against malignant cells.
  • Unlike conventional chemotherapy — which exerts cytotoxic effects on all rapidly dividing cells — immunotherapy is designed to achieve tumor-selective killing while generating immunological memory capable of preventing relapse.
  • The principal biological targets include immune checkpoint proteins (PD-1, PD-L1, CTLA-4, LAG-3, TIM-3), tumor-infiltrating lymphocyte (TIL) pathways, and surface antigens uniquely expressed on cancer cells such as CD19, CD20, HER2, and EGFR.
Full details →

Who is a Candidate?

  • ELIGIBILITY CRITERIA:
  • Patients with histologically or cytologically confirmed solid tumors or hematologic malignancies for whom immunotherapy has regulatory approval or strong Level 1 evidence (e.g., NSCLC, melanoma, bladder cancer, RCC, HCC, MSI-H colorectal cancer, triple-negative breast cancer, classical Hodgkin lymphoma, diffuse large B-cell lymphoma)
  • Patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or large B-cell lymphoma who have failed ≥2 prior lines of systemic therapy (CAR-T eligibility)
  • ECOG Performance Status 0–2 (patients with PS 3–4 are generally not candidates for aggressive immunotherapy unless performance decline is directly disease-related and reversible)
  • +20 more

Treatment Options & Approaches

  • CHECKPOINT INHIBITOR THERAPY (ANTI-PD-1 / PD-L1 / CTLA-4):

Recovery

  • PHASE 1 — PRE-TREATMENT EVALUATION (WEEKS 1–3, OFTEN COMPLETABLE REMOTELY):

Risks to be aware of

  • Cancer immunotherapy carries a distinct and clinically significant toxicity profile that differs fundamentally from conventional chemotherapy.
  • The most consequential category is immune-related adverse events (irAEs), which result from non-specific immune activation affecting normal tissues.
Full details →

Why GAF Healthcare

  • GAF Healthcare provides a fully integrated, end-to-end medical travel coordination service that removes logistical barriers at every stage of the immunotherapy journey, allowing patients and their families to focus entirely on treatment and recovery.

Cost Range for Related Procedures

Cancer Surgery$4,000$15,000
Chemotherapy$1,000$4,000
Radiation Therapy$3,500$10,000
Get a personalised estimate with our cost calculator →

Common questions about Immunotherapy for Cancer

What is the cost of Cancer Immunotherapy in India vs. the UAE?
The cost of cancer immunotherapy varies considerably depending on the specific agent or combination regimen, the number of treatment cycles required, and whether advanced modalities such as CAR-T cell therapy are part of the protocol. In India, a full course of checkpoint inhibitor therapy (e.g., pembrolizumab every 3 weeks for 6–12 months) typically costs between USD 8,000 and USD 45,000, while CAR-T cell therapy (including leukapheresis, manufacturing logistics, conditioning chemotherapy, infusion, and monitoring) ranges from approximately USD 40,000 to USD 75,000 at leading JCI- and NABH-accredited oncology centers in Mumbai, Delhi, Chennai, and Hyderabad. In the UAE (Dubai and Abu Dhabi), equivalent checkpoint inhibitor protocols range from USD 18,000 to USD 65,000, while CAR-T programs at JCI/DHA-accredited hospitals in Dubai Healthcare City and Abu Dhabi typically range from USD 80,000 to USD 140,000 — still representing a 60–70% cost reduction compared to the United States, where CAR-T product costs alone exceed USD 375,000–465,000 before hospital fees. The cost advantage in India is primarily driven by lower drug acquisition costs (domestic manufacturing of biosimilar checkpoint inhibitors is permitted), lower operational costs, and high treatment volume. The UAE commands a premium reflecting luxury hospital infrastructure, advanced nursing ratios, and geographic convenience for patients from the Middle East, GCC, and Africa. In both destinations, GAF Healthcare provides transparent, itemized cost estimates with no hidden fees before any commitment is made.
How long do I need to stay in the country before I am fit to fly home?
The minimum in-country stay required before you are medically cleared for international air travel depends significantly on the specific immunotherapy modality you receive. For checkpoint inhibitor therapy (pembrolizumab, nivolumab, ipilimumab, or combination regimens): The initial workup, biomarker testing, and Cycle 1 administration typically require 2–3 weeks in-country. Once Cycle 1 is complete and no Grade 2 or higher immune-related adverse events (irAEs) are present, most patients receive fit-to-fly clearance after 3–4 weeks total. Subsequent cycles (typically every 3–6 weeks) can often be administered at a GAF Healthcare partner facility closer to your home country. For CAR-T cell therapy: This requires a longer and non-negotiable in-country commitment. After leukapheresis (Day 1), there is typically a 2–4 week wait for cell manufacturing. Lymphodepleting chemotherapy begins 2–3 days before CAR-T infusion. Post-infusion, a minimum of 4 weeks of mandatory inpatient and outpatient monitoring is required to manage cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which can onset up to Day 14. A 28–30 day response assessment PET-CT is performed before discharge planning begins. The minimum realistic total in-country duration for CAR-T patients is 8–10 weeks. For all patients, a formal fit-to-fly letter is issued by the treating oncologist, and GAF Healthcare provides a structured medical summary for cabin crew and customs if required. Long-haul flights carry additional DVT risk in immunocompromised patients, and low-molecular-weight heparin prophylaxis may be recommended depending on thrombotic risk assessment.
What is the success rate of Cancer Immunotherapy?
The success rate of cancer immunotherapy is highly context-dependent and must be interpreted based on cancer type, molecular biomarker profile, treatment line, and the specific modality used. There is no single universal success rate; the figures below reflect the strongest published clinical data. For PD-1/PD-L1 checkpoint inhibitors in solid tumors: Objective response rates (ORR) range from 15–45% depending on PD-L1 expression and TMB status. In NSCLC with PD-L1 TPS ≥50%, pembrolizumab monotherapy achieves an ORR of approximately 45% and a 5-year overall survival rate of ~31% (Keynote-024 long-term follow-up). In metastatic melanoma treated with dual checkpoint blockade (nivolumab + ipilimumab), 5-year overall survival is approximately 52% (CheckMate 067). Patients with MSI-H/dMMR tumors across any cancer type treated with pembrolizumab or dostarlimab demonstrate ORRs of 40–57%, with a significant subset achieving durable complete responses. For CAR-T cell therapy: In relapsed/refractory large B-cell lymphoma, axicabtagene ciloleucel achieves complete remission rates of 58–73% in the third-line setting, with approximately 40% of patients maintaining response at 24 months. In relapsed/refractory B-cell ALL in pediatric/young adult patients, tisagenlecleucel achieves complete remission in approximately 81% of cases. For multiple myeloma treated with BCMA-targeting CAR-T (ciltacabtagene autoleucel), ORRs exceed 98% with stringent complete response rates of ~73% in heavily pretreated populations. It is essential to understand that 'success' in oncology is measured across multiple endpoints: overall survival, progression-free survival, complete remission, quality of life, and durable disease control. GAF Healthcare's partner oncologists provide individualized probability estimates based on your specific tumor profile, biomarker results, and treatment history during the initial teleconsultation — before any financial or travel commitment is made.

How GAF Healthcare Assists in Choosing the Best Hospital for Immunotherapy for Cancer in Delhi NCR, India

Discover the Top Hospitals for Immunotherapy for Cancer in Delhi NCR, India

This page lists 35 accredited cancer care hospitals in Delhi NCR, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Common Questions

Frequently asked questions about immunotherapy for cancer in Delhi NCR, India

How many cancer care hospitals are listed in Delhi NCR, India?
35 hospitals in our Delhi NCR, India directory are currently listed for cancer care including Immunotherapy for Cancer.
How do you choose which hospitals to list?
A hospital appears on this page when Cancer Care is among its listed specialties and it is located in Delhi NCR, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there cancer care hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH, NABL, ISO — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for immunotherapy for cancer?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about immunotherapy for cancer in Delhi NCR, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for immunotherapy for cancer in Delhi NCR, India.

Contact us to report an inaccuracy on this page.